Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

GSK’s global performance showed strength across key markets. Sales in the United States reached £16.4 billion, up 6% at ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.